|
|
|
Micromet,
TRACON in $100M Pact to Develop and Commercialize Antibody
for Cancer Treatment |
|
|
| March
16, 2007--TRACON
Pharmaceuticals has obtained exclusive worldwide rights to
develop and commercialize Micromet’s D93 humanized
antibody for the treatment of cancer. TRACON
plans to initiate a Phase I trial in the second half of
this year. TRACON will pay Micromet upfront and milestone
payments of more than $100 million, if D93 is successfully
developed and commercialized. In addition, Micromet will
receive royalties on worldwide sales of D93. TRACON
Pharmaceuticals |
|
|
|
|
|
|
